IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company pioneering the development of novel treatments for Parkinson’s disease, will be releasing its year-end report and presentation on Thursday, February 23 at 07:00 CET. The report will cover the period of January-December 2022 and will provide an in-depth look into IRLAB’s progress towards creating innovative treatments for Parkinson’s.
On February 23, 2023, join us for an exclusive online webcast at 10:00 CET to get a first-hand look at the company’s year-end report for the period January-December 2022. CEO Richard Godfrey and EVP and Head of R&D Nicholas Waters will be on hand to discuss the report and answer any questions you may have. Don’t miss this unique opportunity to get the inside scoop on the company’s financial performance!
IRLAB is a biopharmaceutical company dedicated to discovering and developing innovative treatments for neurological disorders, such as Parkinson’s disease. Its two most advanced clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), are currently in Phase IIb clinical trials and are designed to address the most challenging symptoms related to Parkinson’s. In 2021, leading specialty pharma company Ipsen acquired exclusive global rights to develop and commercialize mesdopetam, further demonstrating IRLAB’s commitment to advancing novel treatments for neurological disorders.
IRLAB, a biotechnology company listed on Nasdaq Stockholm, has developed a revolutionary research platform called Integrative Screening Process (ISP) to uncover innovative drug candidates for the treatment of CNS disorders. Leveraging its ISP platform, IRLAB has developed a strong clinical pipeline, as well as three preclinical programs, IRL942, IRL757, and IRL1117, which are on track for Phase I studies. With its cutting-edge technology, IRLAB is striving to revolutionize drug discovery and development in the healthcare industry.